Is Carfilzomib available in Hong Kong?

Carfilzomib is an important drug used to treat multiple myeloma (Multiple Myeloma), a malignant cancer of the bone marrow. It belongs to a class of drugs called proteasome inhibitors, whose main function is to prevent the degradation of proteins in the proteasome, leading to the death of cancer cells.

Carfilzomib has been launched in China and is included in medical insurance. Patients can purchase it domestically at a price of around 8,000 to 9,000 yuan. Please consult the local hospital pharmacy for specific prices. The prices in Hong Kong hospital pharmacies are higher than those in China. Foreign countries mainly use the original drug of carfilzomib, and the cheaper one is the European version of the original drug, which costs around 5,000. And the medicinal ingredients and efficacy are the same as those of domestic original medicines.

Carfilzomib prevents protein degradation in cancer cells by specifically inhibiting the function of the proteasome. This leads to a buildup of abnormal leukemia cells, eventually causing them to die. This mechanism helps control the spread and proliferation of multiple myeloma.

Carfilzomib has been widely shown to be highly effective in treating multiple myeloma. It is often used along with other medications such as immune modulators and hormonal therapies to increase the effectiveness of treatment. The introduction of carfilzomib provides an important treatment option for patients who are resistant or intolerant to other treatment modalities.

Carfilzomib is usually given as an intravenous injection. This needs to be done in a hospital or treatment center to ensure proper medication delivery and patient safety. The dosage of carfilzomib is based on the patient's specific condition and treatment plan. Treatment usually consists of an initial cycle, and may then be continued with maintenance therapy to prevent recurrence. Dosage and treatment cycles will vary based on the patient's condition and response.

Although carfilzomib is highly effective in treating multiple myeloma, it may cause side effects including cardiotoxicity, pulmonary toxicity, hypertension, bleeding, nausea, vomiting, diarrhea, anemia, and renal impairment. Therefore, when using carfilzomib, patients need to receive regular medical monitoring to ensure the effectiveness of treatment and to promptly manage discomfort or side effects.